Information about Aglaia Oncology Fund
My details
*
*
*

Company information

Status
Active

KVK number

34202861

VAT Number

NL 812930277 B01
Established
18-02-2004
Last balance sheet year
2025
Company size
Small 2 FTE
Legal form
Besloten Vennootschap (BV)
RSIN number
812930277
Principal activity
Specialised medical care without overnight stay (not psychiatric care)
Health barometer
Credit limit
Detailpage

Are you looking for more information about this company?

  • Consult health at a glance

  • Choose quick insights or granular details

  • Get updates on important developments

7-day free trial, no credit card required.

Financial data from Aglaia Oncology Fund

2025 2024 2023 2022
Balance sheet
Balance sheet total € 745.233 2% € 731.764 -13% € 845.578 > 1000% € 1.001
Equity € 740.154 2% € 726.621 145% € 297.167 494% € -75.436
Debts € 5.079 -1% € 5.143 -99% € 548.411 617% € 76.437
Other
Employees 0 0 0 0

Frequently asked questions

What is the KVK number of Aglaia Oncology Fund?
The KVK number of Aglaia Oncology Fund is 34202861
What is the VAT number of Aglaia Oncology Fund?
The VAT number of Aglaia Oncology Fund is NL 812930277 B01.
Wat is the PEPPOL ID of Aglaia Oncology Fund?
There is no information available about the PEPPOL ID of Aglaia Oncology Fund or the company is not yet registered on the PEPPOL network.
When was Aglaia Oncology Fund founded?
Aglaia Oncology Fund was founded on 18-02-2004.
What is the address of Aglaia Oncology Fund?
The current registered office of Aglaia Oncology Fund is located at Professor Bronkhorstlaan 10/92 G, 3723 MB Bilthoven.
When was the last time Aglaia Oncology Fund filed their annual financial statements?
The most recent financial statements of Aglaia Oncology Fund were filed on 31-12-2025.
How many employees does Aglaia Oncology Fund have?
There are 2 FTEs working at Aglaia Oncology Fund according to the staff figures in the most recent financial statements.
What is the annual turnover of Aglaia Oncology Fund?
There is no turnover available for Aglaia Oncology Fund.